The results of this study demonstrate that CSPG4 directed therapies may be applicable to chondrosarcomas with over 70% of patients in our cohort demonstrating moderate to high expression in conventional chondrosarcoma. The gene discussed is CSPG4; the disease is chondrosarcoma.